Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 5/20 | 0.46 |
| ▸ | JAK2 | O60674 | 13/20 | 0.43 |
| ▸ | JAK1 | P23458 | 12/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021994 | 0.94 | KDM1A (0.45) | AXLJAK2JAK1TYK2STAT3 | |
| SCHEMBL4560124 | 0.93 | AXL (0.45) | AXLJAK2JAK1TYK2STAT3 | |
| SCHEMBL5022123 | 0.92 | KDM1A (0.50) | AXLJAK2JAK1TYK2JAK3 | |
| SCHEMBL4561206 | 0.92 | JAK2 (0.45) | JAK2JAK1HDAC1HDAC6TYK2 | |
| SCHEMBL4561732 | 0.89 | KDM1A (0.55) | AXLJAK2JAK1TYK2JAK3 | |
| SCHEMBL5021908 | 0.87 | KDM1A (0.43) | JAK2JAK1TYK2STAT3JAK3 | |
| SCHEMBL4561292 | 0.87 | ALDH1A1 (0.46) | JAK2JAK1TYK2STAT3JAK3 | |
| SCHEMBL4560651 | 0.87 | AXL (0.43) | AXLJAK2JAK1TYK2STAT3 | |
| SCHEMBL4562570 | 0.86 | IGF1R (0.48) | JAK2JAK1TYK2STAT3JAK3 | |
| SCHEMBL4561894 | 0.86 | JAK3 (0.46) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012062704-A1 | PYRIDINE COMPOUNDS AND AZA ANALOGUES THEREOF AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |